Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Research and Development | May 07, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,016 |
Reported balance
After 2026-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-07 · Tax withholding · Disposed 446 · Balance 30,016 F1: These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 23:36 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 446 | $331.11 | $147,675.06 |
DisclosureSEC source: 0000318154-26-000083 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,016 F1 · balance_after: These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 06, 2026 Filed May 8, 2026 01:14 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 407 | $329.59 | $134,143.13 |
DisclosureSEC source: 0000318154-26-000082 · form4.xml · nonDerivative · entry 2 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,462 F2 · balance_after: These shares include 1,332 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 05, 2026 Filed May 8, 2026 01:14 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 21,773 | $329.59 Strike: $329.59 | $7,176,163.07 |
DisclosureSEC source: 0000318154-26-000082 · form4.xml · derivative · entry 3 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,773 Underlying: Common Stock · 21,773 shares Expires 2036-05-05 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027. Read SEC document |
| May 05, 2026 Filed May 8, 2026 01:14 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,337 | $0.00 | $0.00 |
DisclosureSEC source: 0000318154-26-000082 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,869 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 23:39 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 953 | $384.32 | $366,256.96 |
DisclosureSEC source: 0000318154-26-000006 · form4.xml · nonDerivative · entry 2 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,378 F1 · balance_after: These shares include 1,205 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 23:39 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,151 | $384.32 | $826,672.32 |
DisclosureSEC source: 0000318154-26-000006 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,331 Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:49 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 22,944 | $270.44 Strike: $270.44 | $6,204,975.36 |
DisclosureSEC source: 0001127602-25-013778 · form4.xml · derivative · entry 2 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,944 Underlying: Common Stock · 22,944 shares Expires 2035-05-06 F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and are exercisable in four equal annual installments of 25% each commencing on 5/6/2026. Read SEC document |
| May 06, 2025 Filed May 9, 2025 00:49 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013778 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,753 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 948 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:59 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 18,603 | $300.30 Strike: $300.30 | $5,586,480.90 |
DisclosureSEC source: 0001127602-24-014850 · form4.xml · derivative · entry 2 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,603 Underlying: Common Stock · 18,603 shares Expires 2034-05-07 F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:59 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014850 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,438 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively. F2 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028; and 2,863 RSUs which will vest in installments of 944 on 5/7/2026, 945 on 5/7/2027, and 974 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 182 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 13,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004620 · form4.xml · nonDerivative · entry 2 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,393 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively. F2 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan: 8,587 RSUs which will vest in installments of 2,833 on 2/9/2026, 2,834 on 2/9/2027, and 2,920 on 2/9/2028; and 13,806 RSUs which will vest in installments of 4,555 on 2/9/2026, 4,556 on 2/9/2027, and 4,695 on 2/9/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 00:50 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 8,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004620 · form4.xml · nonDerivative · entry 1 Bradner James E. · CIK 0002005159 · EVP, R&D, & Chief Sci. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,587 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 2/9/2026, 2/9/2027 and 2/9/2028, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.